Endonovo Therapeutics, Inc. (ENDV): Depreciation & Amortization
Not updated since 2022-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$646.9K
Year ended 2022-12-31
-0.2%
3-year compound annual growth
+113.0%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2022-12-31 | $646.9K | -0.2% | 2023-04-17, From 2022-01-01 |
| 2021-12-31 | $648.5K | -0.4% | 2023-04-17, From 2021-01-01 |
| 2020-12-31 | $651.2K | +0.1% | 2022-04-14, From 2020-01-01 |
| 2019-12-31 | $650.3K | 0.0% | 2021-04-13, From 2019-01-01 |
| 2018-12-31 | $650.2K | n/m | 2020-05-04, From 2018-01-01 |
| 2017-12-31 | $14.8K | -6.8% | 2019-04-15, From 2017-01-01 |
| 2016-12-31 | $15.8K | +7.2% | 2018-04-06, From 2016-01-01 |
| 2015-12-31 | $14.8K | -6.1% | 2017-04-17, From 2015-01-01 |
| 2014-12-31 | $15.7K | +31.5% | 2016-05-17, From 2014-01-01 |
| 2013-12-31 | $12.0K | n/a | 2015-06-15, From 2013-01-01 |